Zhao Kun, Mao Yukang, Li Yansong, Yang Chuanxi, Wang Kai, Zhang Jing
Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Department of Cardiology, Yangpu Hospital, Tongji University School of Medicine, Shanghai, China.
Front Cardiovasc Med. 2022 Aug 26;9:952949. doi: 10.3389/fcvm.2022.952949. eCollection 2022.
Pathological myocardial remodeling was still one of the leading causes of death worldwide with an unmet therapeutic need. A growing number of researchers have addressed the role of epigenome changes in cardiovascular diseases, paving the way for the clinical application of novel cardiovascular-related epigenetic targets in the future. In this review, we summarized the emerged advances of epigenetic regulation, including DNA methylation, Histone posttranslational modification, Adenosine disodium triphosphate (ATP)-dependent chromatin remodeling, Non-coding RNA, and RNA modification, in pathological myocardial remodeling. Also, we provided an overview of the mechanisms that potentially involve the participation of these epigenetic regulation.
病理性心肌重塑仍是全球主要死因之一，治疗需求尚未得到满足。越来越多的研究人员探讨了表观基因组变化在心血管疾病中的作用，为未来新型心血管相关表观遗传靶点的临床应用铺平了道路。在本综述中，我们总结了表观遗传调控在病理性心肌重塑中出现的进展，包括DNA甲基化、组蛋白翻译后修饰、三磷酸腺苷（ATP）依赖的染色质重塑、非编码RNA和RNA修饰。此外，我们概述了可能涉及这些表观遗传调控参与的机制。
